• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this presentation? Why not share!

Crb Bio Ii Summary Nov2010 Eng

on

  • 687 views

Brief presentation of new Biotech VC Fund promoted by CRB Inverbio

Brief presentation of new Biotech VC Fund promoted by CRB Inverbio

Statistics

Views

Total Views
687
Views on SlideShare
680
Embed Views
7

Actions

Likes
0
Downloads
4
Comments
0

1 Embed 7

http://www.linkedin.com 7

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Crb Bio Ii Summary Nov2010 Eng Crb Bio Ii Summary Nov2010 Eng Presentation Transcript

    • CRB Bio II: A New Investment Opportunity in Biotech
      November, 2010
    • A Unique Spanish Biotech Initiative
      A new Venture Capital Fund specialized in early stage investment in the biotechnology sector with a target fund size of €60 million.
      • The Fund will be managed by a new Venture Capital Firm (CRB Inverbío) created by the founding partners of Cross Road Biotech, a Spanish venture capital company with wide experience and track record in biotech project management.
      • Cross Road Biotech currently has a diversified portfolio of eleven companies in the biomedicine sector at different stages of development.
      • Cross Road Biotech has achieved a unique know how in the Spanish venture capital market specialized in biotechnology and its portfolio will generate net returns several times higher than the investment.
      Cross Road Biotech SCR - ConfidentialInformation
      P. 2
      • The new Fund is anchored on six differential competitive advantages to generate high financial returns
      3
      A Unique Spanish Biotech Initiative
      Cross Road Biotech SCR - ConfidentialInformation
    • Founding Team of CRB Inverbío
      Executive Team -
      Founding partners
      Enrique Castellón – CEO & Chairman
      PhD in Medicine, Economist. Former Secretary of State for Health and Consumers in the Health and Consumer Ministry. Chairman of the Spanish Medicines' Agency. Creation of national oncological research centers (CNIO) and cardiovascular disease centers (CNIC). Deputy minister for Health and Social Services in the region of Madrid . General Manager of the health service of Galicia
      Pablo Cabello – Technical and Scientific Director
      Molecular Biologist. Professional experience in the Instituto de Biología Celular.
      Histopathology services in the Fundación Jiménez Diaz Hospital.
      20 years in the Molecular Genetics laboratory of the Hospital Ramón y Cajal.
      Manuel Castellón– Managing Director.
      Lawyer and Economist. Master in Legal Counselling. 25 years of experience as corporate lawyer . Director and certified company counsel in various companies including Antena 3 Radio and Grupo Prisa. Founder of Castellón Abogados.
       
      Angel Santos – Director of Business Development
      Engineer. Has developed his career in Spain, the UK and the US in companies such as Johnson's Wax and Lilly, in which he has held different leadership positions in general management, strategic and corporate development, M&A, business development and innovation management.
      P. 4
      Cross Road Biotech SCR - ConfidentialInformation
    • Cross Road Biotech: a history of success
      11 Companies
      +€32M invested
      82 job creation
      38 patents
      CRB Capital Increase
      CRB has demonstrated capacity identifying and developing biotechnology companies in the human health sector, creating value for shareholders
      P. 5
      Cross Road Biotech SCR - ConfidentialInformation
    • Current portfolio. Companies
      P. 6
      - Cross Road Biotech SCR - Confidential Information
    • Current portfolio. Companies
      P. 7
      - Cross Road Biotech SCR - Confidential Information
    • Current portfolio. Companies
      P. 8
      - Cross Road Biotech SCR - Confidential Information
    • Current portfolio. Equity Position
      siRNA THERAPEUTICAL APPLICATIONSNANOTECHNOLOGY
      DRUG DELIVERY
      FARMACOGENOMICS
      4,5%
      (2006)
      (2007)
      (2010)
      LACTOSE INTOLERANCE
      51,4%
      (-)
      (2009)
      (2010)
      ONCOLOGY
      63,4%
      (-)
      (2011)
      (2013)
      VIH DIAGNOSTICS
      99,7%
      (-)
      (2010)
      (2010)
      LIVER DISEASES AND METABOLOMICS
      41,7%
      (2006)
      (2009)
      (2013)
      ALZHEIMERDIAGNOSTICS
      90,8%
      (-)
      (-)
      (2011)
      ServicesProductsDivestment
      Se
      100%
      (-)
      (-)
      (2010)
      50%
      (-)
      (-)
      (2014)
      PREIMPLANTATIONALDIAGNOSIS
      CRB 5%
      OWL 30%
      (2010)
      (2011)
      (2014)
      ONCOLOGY
      74,9%
      (-)
      (-)
      (2013)
      P. 9
      Cross Road Biotech SCR - ConfidentialInformation
    • The Management Team of CRB promotes the creation of a new Venture Capital Firm named CRB Inverbío
      • The partners and founders of CRB have achieved a unique know how in the Spanish venture capital market specialized in biotechnology.
      • The constitution of a new fund promoted by the Venture Capital Firm will give continuity to CRB´s entrepreneurial initiative.
      • There are many new projects with great potential that can be consider into the new structure of CRB Inverbío.
      • CRB Inverbío fills in a market segment that does not count with other parties, which represents an opportunity for accessing proprietary investments and thus, a competitive advantage.
      • There is an increasing interest from the regional and local governments and institutions in promoting specialized investment vehicles in biotechnology.
      • CRB Inverbío is well positioned to be the reference partner to this initiatives.
      P. 10
      Cross Road Biotech SCR - ConfidentialInformation
    • Outline of the Transition
      Venture Capital Firm
      Managing Team
      Managing Team
      CRB SCR
      Current CRB portfolio
      BIO II
      Fund
      Other Funds
      New Projects
      P. 11
      Cross Road Biotech SCR - ConfidentialInformation
    • Vision and Mision of the new BIO II Fund
      Vision
      The most profitable Spanish fund specialized in life sciences at initial stages, developing business projects based on new scientific solutions that cover unmet medical and or technological needs.
      Mision
      • To select the best business projects based on advanced science and technology and with great opportunities for value creation.
      • To guarantee the best development, financing and strategic management until the clinic or industrial proof of concept that maximizes the value equation.
      • Divest with added value that will assure big returns to the investors.
      P. 12
      Cross Road Biotech SCR - ConfidentialInformation
    • Strategy and magnitudes of the new Bio II Fund
      Name: CRB Bio II Fund
      Size of Fund: €60 M first close November 2010
      Duration: 8 years (+2)
      Investment period: 3 years (+1)
      Minimum investment: Depending upon project needs
      Maximum investment: up to 15% of the fund
      Follow-on Investment paced in multiple rounds upon milestone achievement
      Number of investments: 10-12
      Investment outside Spain: max 10%
      Investment in biomedicine: up to 80%
      Investment in med tech: up to 10%
      Investment in other life sciences: up to 20%
      Cross Road Biotech SCR - ConfidentialInformation
      13
    • Investment Strategy will look for a balanced portfolio
      • Technology and field of operation
      The investment strategy mandates the majority of the Fund to be invested in the biomedicine field as this is the area where CRB has developed its expertise and know how.
      However the new Fund will extend its reach and consider investments in closely related fields of operations and technologies including:
      Agriculture and Animal health
      Medical Devices and medical technologies
      Bioinformatics
      There are many opportunities in these areas, in general require shorter development and maturation time and are less capital intensive and still have good exit options, therefore representing a good option to balance the portfolio.
      The new Fund will not invest in industrial biotech.
      14
      Cross Road Biotech SCR - ConfidentialInformation
    • Timing for the incorporation of the Fund
      2010
      2011
      2Q3Q 4Q 1Q 2Q
      Venture Capital Investment Firm incorporation (CRB Inverbío)
      CRB Bio II Fund incorporation
      Fund raising
      1st Fund closing
      2nd Fund closing
      Ordinary operations
      30/XII
      30/IV
      15
      Cross Road Biotech SCR - Confidential Information
    • Almagro 1, 1º derecha
      28010 Madrid, Spain
      Tel.: +00 34 91 446 7897
      Email: info@crbinverbio.com
      Web: www.crossroadbiotech.com